Monthly Archives: July 2008

Gurkhas lose pension legal battle

Former Gurkha soldiers have lost their High Court battle over a pensions deal with the British Government they say has left them struggling to live.

Three retired members of the famous Brigade of Gurkhas failed in a legal challenge affecting thousands of others.

Lawyers for the three - Kumar Shrestha, Kamal Purja and Sambahadur Gurung, all in their late 30s and retired because of ill health - argued they had been treated unlawfully and unfairly.

They said men who enlisted before July last year but retired after had been denied equal pensions because their years of service up to that date were valued at only between 24 per cent and 36 per cent of British rates.

The Gurkhas complained that the new pension transfer arrangements enacted last year were irrational and discriminated against them on the grounds of age.

Rejecting their application for judicial review, Mr Justice Ouseley said the MoD had acted reasonably.

He said: “If there was indirect discrimination on the grounds of age or ‘other status’, it was justified and proportionate.”

Legal victory for AstraZeneca in Seroquel case

A US court has granted the company’s request for a summary judgement in the case in which AstraZeneca is suing Teva Pharmaceuticals and Sandoz for alleged patent infringement.

The two companies being sued had sought approval to sell generic versions of Seroquel tablets in the US before Seroquel’s patent expires in 2011.

Teva and Sandoz have already conceded infringement and the validity of AstraZeneca’s patent, but until the latest judgement by the court there was still the possibility of a long trial on the matter on inequitable conduct.

Under US patent law, a court may opt not to enforce a patent, even if it is valid, is the patentee has engaged in inequitable conduct, which can take the form of misrepresentation or omissions during the patent application process.

“We are pleased with the court’s decision to uphold our valid intellectual property. Seroquel remains an important part of our company’s portfolio benefiting patients and physicians throughout the world,” said David Brennan, chief executive officer of AstraZeneca.

Seroquel is AstraZeneca’s second biggest money earner, generating booked sales of $4bn last year.

Pre-Paid Legal Services Announces 2008

Our total active membership fees in force increased approximately 2.0% during the last year and continue our trend of increasing our membership fees. Membership persistency rate (defined as the number of memberships in force at the end of a 12 month period as a percentage of the total of memberships in force at the beginning of such period, plus new memberships sold during such period) was 73.3% for the 12 month period ended June 30, 2008 an increase from the 72.7% for the 12 month period ended June 30, 2007.

Our second quarter 2008 corporate finance focus has again been on share repurchases. During the 2nd quarter, we returned $14.9 million to shareholders through the repurchase of 343,409 shares of common stock, at an average per share price of $43.33. Since April 1999, we have returned $390.2 million to shareholders through the purchase of 13.3 million shares, average price of $29.30 per share, and $17.1 million in dividends for a combined total of $407.3 million representing more than 115 percent of our net earnings during the same timeframe.

Hello world!

Welcome to WordPress. This is your first post. Edit or delete it, then start blogging!